SCHEMBL30830598

SCHEMBL30830598

CCn1ncc(N[C@@H]2C[C@H](c3ccc(C(=O)O)cc3)CN(C)C2)c(Br)c1=O

nearest known ligand 0.62

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 17/20 0.62
▸ BRD9 Q9H8M2 3/20 0.62
▸ BPTF Q12830 2/20 0.62
▸ KAT2A Q92830 2/20 0.62
▸ BRD1 O95696 1/20 0.62
▸ ACHE P22303 1/20 0.62
▸ BRPF1 P55201 1/20 0.62
▸ BRD7 Q9NPI1 1/20 0.62
▸ BAZ2B Q9UIF8 1/20 0.62
▸ BRPF3 Q9ULD4 1/20 0.62
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ SETDB1 Q15047 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830841 0.89 KAT2B (0.56) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830559 0.89 KAT2B (0.79) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830681 0.81 KAT2B (0.55) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL31091698 0.80 KAT2B (0.68) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830474 0.80 KAT2B (0.62) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL31091696 0.80 KAT2B (0.62) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830795 0.79 KAT2B (0.73) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830560 0.79 KAT2B (0.73) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL30830592 0.79 KAT2B (0.79) KAT2BBRD9BPTFKAT2ABRD1
SCHEMBL31091709 0.78 KAT2B (0.60) KAT2BBRD9BPTFKAT2ABRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback